

September 30, 1968

Dr. Carl Salzman
National Institute of Mental Health
5454 Wisconsin
Chevy Chase, Maryland

Dear Carl,

Enclosed are copies of sample out-puts of our laboratory data. These samples are selected from the butaperazine study that we recently completed. The output is based on the 1966 MIP laboratory data scale.

In working with that form for the past year, we have learned both that there are important omissions, and that the form lists many tests rarely or never performed. Based on this experience, we have modified the form and enclose our sample copies of our present effort.

I would like to suggest that duplicate out-puts and laboratory forms be sent to the ECDEU investigators and that this become a subject for discussion at a meeting of the investigators. In the event that any investigator or you would wish to have a demonstration of the application of the form to a definite set of data, we will be pleased to supply the test forms and carry out the analyses.

I am also enclosing a reprint of the controlled laboratory study which my associates and I completed in Missouri. As I indicated, I have been concerned with the seeming peremptory dismissal of iproniazid for the alleged effects on liver function. The data is not too clear in this regard and much of it is without sufficient control. If a central laboratory review were established for a variety of new drugs, for standard drugs and for different populations under no drug conditions, then the experience might be broad enough to provide a firmer basis for such decisions in the future. We would like to suggest that such a record facility be established.

I look forward to visiting you, Jerry, Bill Guy and Ron Bonato in Washington, hopefully on October 18. My best regards.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp